Source: Zacks

GSK: GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal

GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.

Read full article »
Annual Revenue
$42.3B
Employees
90,096
Dame Emma Walmsley's photo - CEO of GSK

CEO

Dame Emma Walmsley

CEO Approval Rating

67/100

Read more